CarryGenes’ chromosome platform will revolutionize how we treat solid cancer.
With a proprietary human synthetic chromosome (hSynC) as a carrier for antitumoral factors (OncoSynC) introduced into the patient’s own T-cells, CarryGenes’ Cromo-T will create a state of long-term vaccination against the patient’s tumor using immune cells loaded with an enhanced tumor-killing capacity.
CarryGenes is a merge of technologies, a fusion of expertise in immunotherapy, biomedical sciences, and chromosome bioengineering. With a lifelong passion for science and improving human health, the team has a joint ambition to use their knowledge to help other humans.
